THYROCARE TECH LTD

542.2 -3.77 (-0.7%) Sell

THYROCARE continues its fall as more investors loose confidence

13 min read

THYROCARE TECH LTD underperformed today. It lost -0.7% to close at 542.2. During the last week it lost -1.23% and saw a maximum drawdown of -1.23%.

[Themes containing THYROCARE]

Buy-and-Hold investors in THYROCARE experienced a maximum drawdown of -9.96% over the last three months. It lost -7.03% during this down trending period. There were no long signals during this period, where the short signal generated good profits of +7.03% for investors.

Trend

THYROCARE has been underperforming the NIFTY-50 index in recent time, after having outperformed till 3 Jan, 2017. Over the last 2 years 8 months and 9 days, THYROCARE underperformed the NIFTY-50 index on 54% days.

During the last three months THYROCARE was mostly loss making and delivered on average -0.11% per day. It's best return during this period (of +2.25%) was on Thursday, 29 Nov, 2018. While it's worst loss in the same period (of -3.58%) was on Monday, 26 Nov, 2018. There was initially a bearish trend during this period which started on 23 Oct, 2018 and went on till 29 Oct, 2018. The trend delivered -5.15% losses to investors. This was followed by a bullish trend that started on 27 Nov, 2018 and ended on 3 Dec, 2018. This bullish trend delivered +5.98% to investors.

THYROCARE had 4 profitable and 8 loss making months over the last year. During the last year, THYROCARE underperformed NIFTY-50 index on monthly return basis. THYROCARE was also a more risky investment than NIFTY-50 index as it's worst month in the last year, Oct 2018, returned -13.6% compared to -6.42% returned by NIFTY-50 index in Sep 2018. THYROCARE had a longer winning streak of losing months than NIFTY-50 index. It went down in 4 straight months (from Sep 2018 to Dec 2018) during which period it delivered -18.57%. It is interesting to note that both THYROCARE and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

"Experience taught me a few things. One is to listen to your gut, no matter how good something sounds on paper. The second is that you're generally better off sticking with what you know. And the third is that sometimes your best investments are the ones you don't make.

THYROCARE is becoming less volatile overall. In comparison, the NIFTY-50 index is seeing a fall in volatility. During the last three months, there was a significant fall in THYROCARE's volatility from 22 Oct, 2018 to 17 Jan, 2019. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that THYROCARE has significant negative skewness in it's return distribution. This indicates that THYROCARE is very risky for short-term investment and can significantly underperform for long durations.

NIFTY-50 index has more chance of extreme outcomes than THYROCARE. Therefore, NIFTY-50 must receive a lower allocation than THYROCARE in your portfolio. NIFTY-50 index usually has shorter drawdown period than THYROCARE.

On a general note (since you are interested in THYROCARE), RESPONIND is a small cap that deserves to be closely tracked for investment opportunities.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter